基因面板市場－全球產業規模、佔有率、趨勢、機會和預測（按組件、按技術、按最終用戶、按地區和按競爭分類，2020 年至 2030 年）

2024 年全球基因面板市場價值為 29.8 億美元，預計到 2030 年將達到 45.5 億美元，預測期內的複合年成長率為 7.45%。全球基因面板市場正在強勁擴張，這得益於基因檢測在各種疾病的早期診斷和治療中日益成長的重要性。基因面板可以同時分析多個基因，已成為腫瘤學、罕見疾病檢測和藥物基因組學領域的基石。向個人化醫療和標靶治療的轉變顯著促進了基因面板檢測的應用，特別是在遺傳性癌症風險評估、先天性疾病和神經系統疾病方面。下一代定序 (NGS) 技術的進步在這一成長中發揮了關鍵作用，它能夠更快、更準確、更經濟地分析基因變異。基於擴增子和基於雜交捕獲的技術使研究人員和臨床醫生能夠更輕鬆地根據特定的臨床需求客製化基因面板。例如，2023年10月，中國國家藥品監督管理局（NMPA）批准了Geneseeq的非小細胞肺癌（NSCLC）腫瘤突變負荷檢測試劑盒。該試劑盒包含涵蓋425個癌症相關基因的全面基因面板，旨在透過支持肺癌患者更精準的診斷和治療計劃來增強精準腫瘤學。

定序技術成本的下降，以及病患和醫療保健提供者意識的不斷提升，正在加速基因檢測面板在已開發經濟體和新興經濟體的市場滲透。世界各地的醫療保健系統正擴大將遺傳資訊納入臨床工作流程，尤其是在癌症診斷領域。多基因檢測面板如今已頻繁用於指導乳癌、大腸癌和卵巢癌的治療決策。除腫瘤學外，基因檢測面板在心臟病學、傳染病和產前檢測領域也日益受到關注，其應用範圍也不斷擴大。

關鍵市場促進因素

遺傳疾病和慢性病發生率上升

主要市場挑戰

測試和設備成本高昂

主要市場趨勢

人工智慧與機器學習的融合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球基因檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按組件（測試套件和測試服務）
  • 按技術（基於擴增子的方法 vs. 基於雜交的方法）
  • 按最終用戶（學術和研究機構、醫院和診斷實驗室、製藥和生物技術公司）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美基因檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲基因檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區基因檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲基因檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲基因檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 併購
• 產品發布

第 13 章：競爭格局

• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fischer Scientific, Inc.
• QIAGEN NV
• Eurofins Scientific SE
• Foundation Medicine Inc.
• Guardant Health, Inc.
• Myriad Genetic Laboratories Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG

第 14 章：策略建議

第15章調查會社について,免責事項

Global Gene Panel Market was valued at USD 2.98 billion in 2024 and is expected to reach USD 4.55 billion by 2030 with a CAGR of 7.45% during the forecast period. The global gene panel market is witnessing robust expansion, driven by the growing importance of genetic testing in the early diagnosis and treatment of various diseases. Gene panels, which allow simultaneous analysis of multiple genes, have become a cornerstone in the fields of oncology, rare disease detection, and pharmacogenomics. The shift toward personalized medicine and targeted therapies has significantly boosted the adoption of gene panel testing, especially for hereditary cancer risk assessment, congenital disorders, and neurological diseases. Technological advancements in next-generation sequencing (NGS) have been pivotal in this growth, enabling faster, more accurate, and cost-effective analysis of gene variants. Amplicon-based and hybrid-capture based techniques have made it easier for researchers and clinicians to customize gene panels according to specific clinical requirements. For instance, in October 2023, China's National Medical Products Administration (NMPA) approved Geneseeq's tumor mutational burden test kit for non-small cell lung cancer (NSCLC). The kit features a comprehensive gene panel covering 425 cancer-related genes, aiming to enhance precision oncology by supporting more accurate diagnosis and treatment planning in lung cancer patients.

The decreasing cost of sequencing technologies and growing awareness among patients and healthcare providers are accelerating the market penetration of gene panels across both developed and emerging economies. Healthcare systems around the world are increasingly incorporating genetic information into clinical workflows, particularly for cancer diagnostics. Multigene panels are now frequently used to guide treatment decisions in breast, colorectal, and ovarian cancers. Beyond oncology, gene panels are also gaining traction in cardiology, infectious diseases, and prenatal testing, widening their scope of applications.

Key Market Drivers

Rising Incidence of Genetic and Chronic Diseases

The rising incidence of genetic and chronic diseases is a major driver propelling the growth of the global gene panel market. For instance, according to the Genetic and Rare Disease (GARD) Information Center, over 7,000 genetic conditions have been identified, with the number steadily increasing. In the U.S., at least 200,000 individuals live with known genetic disorders, while in the U.K., around 30,000 infants are diagnosed annually, contributing to over 2.4 million survivors. Gene panels are often developed to detect such conditions at birth, enabling timely diagnosis and early intervention through appropriate treatment and management strategies. This early detection plays a crucial role in improving patient outcomes and reducing the long-term burden of genetic diseases. Over the past decade, there has been a significant increase in the prevalence of genetic disorders such as cystic fibrosis, thalassemia, and sickle cell anemia, as well as complex chronic conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. Many of these diseases have a strong genetic component, making early and accurate detection through gene panels a critical aspect of modern diagnostics. Gene panels allow clinicians to analyze multiple genes simultaneously to identify mutations associated with hereditary conditions, enabling timely intervention and better disease management. Cancer, in particular, has seen an alarming rise worldwide, with a growing emphasis on personalized treatment approaches based on individual genetic profiles. Gene panel testing has become an essential tool in oncology, helping to detect germline and somatic mutations that influence cancer susceptibility and treatment response. For instance, BRCA1 and BRCA2 gene panels are widely used to assess the risk of breast and ovarian cancers, guiding both preventive strategies and therapeutic choices. Similarly, chronic illnesses such as diabetes, Alzheimer's disease, and cardiovascular disorders often have underlying genetic factors that can be identified through targeted panels, allowing for more precise risk stratification and personalized care plans.

Key Market Challenges

High Cost of Testing and Equipment

The high cost of advanced filtration systems presents a significant challenge to the global gene panel market. As laboratories increasingly demand high-performance solutions for applications in pharmaceuticals, biotechnology, environmental testing, and academic research, the complexity and technological sophistication of filtration equipment have grown. However, this advancement comes at a cost-systems such as nanofiltration, ultrafiltration, and automated filtration setups require substantial capital investment. For many small- to medium-sized laboratories, especially in developing regions, these costs can be prohibitive. Beyond initial acquisition, ongoing operational expenses further burden end users. Advanced filtration systems often require specialized membranes, maintenance kits, calibration, and sometimes custom configurations to suit specific applications. The need for compatibility with other lab infrastructure or integration into automated workflows can increase the total cost of ownership. In sectors where funding is limited or subject to fluctuations, such as academic or public health labs, high-cost systems may be considered an unjustifiable expenditure, leading to reliance on outdated or less efficient alternatives.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into the global gene panel market is rapidly transforming the landscape of genetic testing and precision medicine. AI and ML technologies enhance the ability to analyze vast amounts of genomic data quickly and accurately, addressing one of the key challenges in gene panel testing-interpreting complex genetic variations and identifying clinically relevant mutations. By leveraging sophisticated algorithms, AI can detect subtle patterns and correlations within genetic datasets that may be missed by traditional methods, leading to improved diagnostic accuracy and personalized treatment recommendations.

In gene panel testing, AI-driven tools are increasingly used for variant classification, predicting pathogenicity, and prioritizing genetic mutations for clinical relevance. Machine learning models trained on large genomic databases help in distinguishing benign variants from those linked to disease, reducing the number of variants of unknown significance (VUS) and enhancing the clinical utility of gene panels. This capability is particularly valuable in oncology, where identifying actionable mutations can guide targeted therapies and immunotherapies, improving patient outcomes. AI and ML enable automation of data processing pipelines, decreasing turnaround times and operational costs, which makes gene panel testing more accessible and scalable. The combination of AI with next-generation sequencing (NGS) platforms has led to the development of comprehensive cancer profiling assays that integrate genomic and epigenomic data, providing a more holistic view of tumor biology. For example, companies like Guardant Health use AI-powered liquid biopsy tests that non-invasively profile cancer-related genetic changes from blood samples, demonstrating the potential for less invasive and more frequent monitoring.

Key Market Players

• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fischer Scientific, Inc.
• QIAGEN NV
• Eurofins Scientific SE
• Foundation Medicine Inc.
• Guardant Health, Inc.
• Myriad Genetic Laboratories Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Gene Panel Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Panel Market, By Component:

• Test Kits
• Testing Services

Gene Panel Market, By Technique:

• Amplicon Based Approach
• Hybridization Based Approach

Gene Panel Market, By End User:

• Academic & Research Institute
• Hospital & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies

Gene Panel Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Panel Market.

Available Customizations:

Global Gene Panel Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Panel Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Test Kits v/s Testing Services)
  • 5.2.2. By Technique (Amplicon Based Approach v/s Hybridization Based Approach)
  • 5.2.3. By End User (Academic & Research Institutes, Hospital & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Gene Panel Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Technique
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Panel Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Gene Panel Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Gene Panel Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.5. By End User

7. Europe Gene Panel Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technique
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Gene Panel Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.5. By End User
  • 7.3.2. Germany Gene Panel Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Gene Panel Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Gene Panel Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Gene Panel Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.5. By End User

8. Asia-Pacific Gene Panel Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technique
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Gene Panel Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.5. By End User
  • 8.3.2. India Gene Panel Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Gene Panel Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Gene Panel Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Gene Panel Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.5. By End User

9. South America Gene Panel Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technique
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gene Panel Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Gene Panel Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Gene Panel Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.5. By End User

10. Middle East and Africa Gene Panel Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technique
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gene Panel Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Gene Panel Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Gene Panel Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Illumina, Inc.
  • 13.1.1. Business Overview
  • 13.1.2. Product Offerings
  • 13.1.3. Recent Developments
  • 13.1.4. Financials (As Reported)
  • 13.1.5. Key Personnel
  • 13.1.6. SWOT Analysis
• 13.2. Agilent Technologies, Inc.
• 13.3. Thermo Fischer Scientific, Inc.
• 13.4. QIAGEN NV
• 13.5. Eurofins Scientific SE
• 13.6. Foundation Medicine Inc.
• 13.7. Guardant Health, Inc.
• 13.8. Myriad Genetic Laboratories Inc.
• 13.9. Bio-Rad Laboratories, Inc.
• 13.10. F. Hoffmann-La Roche AG

14. Strategic Recommendations

15. About Us & Disclaimer